Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 35.46% is in line with its 5-year average of 38.21%, around the middle of its 5-year range (22.39%–44.06%).
1.22% below its 12-month average of 35.90%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 36.76%.
EBITDA MARGIN
35.46%
EBITDA MARGIN AVG TTM
35.90%
EBITDA MARGIN AVG 3Y
37.23%
EBITDA MARGIN AVG 5Y
38.21%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.22%
CURRENT VS 3Y AVG
-4.76%
CURRENT VS 5Y AVG
-7.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Waystar Holding Corp.
Market Cap
$5.06B
EBITDA Margin
35.46%
TTM Avg
35.90%
3Y Avg
37.23%
5Y Avg
38.21%
Market Cap
$5.07B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$5.09B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
Market Cap
$5.19B
EBITDA Margin
-1035.18%
TTM Avg
-586.23%
3Y Avg
-456.90%
5Y Avg
-388.23%
Market Cap
$5.20B
EBITDA Margin
45.70%
TTM Avg
43.81%
3Y Avg
42.07%
5Y Avg
42.46%
Market Cap
$5.21B
EBITDA Margin
-0.42%
TTM Avg
-60.31%
3Y Avg
-158.65%
5Y Avg
-142.10%
Market Cap
$5.21B
EBITDA Margin
-15636.44%
TTM Avg
-8457.23%
3Y Avg
-41454.98%
5Y Avg
-35632.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Waystar Holding Corp. (WAY) | $5.06B | 35.46% | 35.90% | 37.23% | 38.21% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 21.06% | 20.50% | 18.63% | 16.67% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.09B | -395.82% | -536.17% | -471.62% | -471.62% |
| Erasca, Inc. (ERAS)vs › | $4.96B | N/A | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.19B | -1035.18% | -586.23% | -456.90% | -388.23% |
| Doximity, Inc. (DOCS)vs › | $5.20B | 35.56% | 38.69% | 36.58% | 34.55% |
| Sotera Health Company (SHC)vs › | $5.20B | 45.70% | 43.81% | 42.07% | 42.46% |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.21B | -0.42% | -60.31% | -158.65% | -142.10% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | -15636.44% | -8457.23% | -41454.98% | -35632.55% |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.84B | -30.33% | -1782.03% | -5492.00% | -5492.00% |
Gross Margin
69.1%
EBITDA Margin
35.5%
Operating Margin
22.9%
Net Margin
11.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 36.76% |
| 2026-03-31 | 38.84% |
| 2025-12-31 | 32.77% |
| 2025-09-30 | 34.82% |
| 2025-06-30 | 36.31% |
| 2025-03-31 | 38.45% |
| 2024-12-31 | 37.35% |
| 2024-09-30 | 36.37% |
| 2024-06-30 | 22.39% |
| 2024-03-31 | 35.31% |
| 2023-12-31 | 39.87% |
| 2023-09-30 | 38.47% |
| 2023-06-30 | 41.48% |
| 2023-03-31 | 41.34% |
| 2022-12-31 | 41.25% |
| 2022-09-30 | 39.26% |
| 2022-06-30 | 38.57% |
| 2022-03-31 | 36.67% |
| 2021-12-31 | 35.50% |
| 2021-09-30 | 40.75% |
| 2021-06-30 | 44.06% |
| 2021-03-31 | 44.29% |
